{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-077126","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2023-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.219952+00:00","generated_at":"2026-06-13T14:11:09.627906+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"BioXcel shareholders elect three Class II directors, ratify Ernst & Young as auditor","bullets":["Elected directors: Sandeep Laumas (12,360,360 for, 8,899,824 withheld), Michael Miller (21,149,269 for, 110,915 withheld), Michal Votruba (18,041,794 for, 3,218,390 withheld).","Ratified Ernst & Young as auditor for FY2023 with 24,849,840 for, 51,173 against, 7,597 abstained.","Turnout was 24,908,610 shares (85.42% of outstanding) as of April 27, 2023 record date."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-077126","json":"https://secwatch.observer/filing/0001104659-23-077126.json","markdown":"https://secwatch.observer/filing/0001104659-23-077126.md","text":"https://secwatch.observer/filing/0001104659-23-077126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923077126/0001104659-23-077126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923077126/tm2320221d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:11:09.627906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a161fb279dbf86b3f71181d94f36ba8377a0af3c","claim":"BioXcel Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. at the 2023-06-26 meeting.","evidence_excerpt":"Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 24,849,840 51,173 7,597 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923077126/0001104659-23-077126-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-26"}],"fact_type":"shareholder_vote"},{"claim_id":"c2dfe754bb8fabfd5bd6b02c5f336dcd0568fa6e","claim":"BioXcel Therapeutics, Inc. shareholders approved Election of three Class II directors for a term of office expiring on the date of the annual meeting of stockholders in 2026 and until his successor has been duly elected and qualified. at the 2023-06-26 meeting.","evidence_excerpt":"NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Sandeep Laumas, M.D. 12,360,360 8,899,824 3,648,426 Michael Miller 21,149,269 110,915 3,648,426 Michal Votruba, M.D. 18,041,794 3,218,390 3,648,426","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923077126/0001104659-23-077126-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-26"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}